The Impact of Chimerism Patterns and Predonor Leukocyte Infusion Lymphopenia on Survival following T Cell-Depleted Reduced Intensity Conditioned Transplants

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 5, 2007, Pages 550-559

  Shaw, Bronwen E ^a   Byrne, Jenny L ^a   Das Gupta, Emma ^a   Carter, G Ian ^a   Russell, Nigel H ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Chimerism; Donor leukocyte infusions; Reduced intensity

Indexed keywords

ALEMTUZUMAB; BLEOMYCIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MICROCHIMERISM; REDUCED INTENSITY CONDITIONING; SURVIVAL; SURVIVAL RATE; T CELL DEPLETION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CHIMERISM; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; GREAT BRITAIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKOCYTE TRANSFUSION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SIBLING RELATIONS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 34247153887     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.12.451     Document Type: Article

References (41)

1. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
2. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 16 (1998) 2817-2824
3. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 300 (1979) 1068-1073
4. Sullivan K.M., Weiden P.L., Storb R., et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73 (1989) 1720-1728
5. Riddell S.R., Berger C., Murata M., Randolph S., and Warren E.H. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev. 17 (2003) 153-162
6. Zeiser R., Spyridonidis A., Wasch R., et al. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia 19 (2005) 814-821
7. Mapara M.Y., Kim Y.M., Wang S.P., Bronson R., Sachs D.H., and Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 100 (2002) 1903-1909
8. Kolb H.J., Schmid C., Chen X., et al. Adoptive immunotherapy in chimeras with donor lymphocytes. Acta Haematol. 110 (2003) 110-120
9. Huff C.A., Fuchs E.J., Smith B.D., et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 12 (2006) 414-421
10. Lush R.J., Haynes A.P., Byrne J., et al. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (± fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy 3 (2001) 203-210
11. Dey B.R., McAfee S., Colby C., et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 9 (2003) 320-329
12. Huss R., Deeg H.J., Gooley T., et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant. 18 (1996) 767-776
13. Childs R., Clave E., Contentin N., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94 (1999) 3234-3241
14. Baron F., Baker J.E., Storb R., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 104 (2004) 2254-2262
15. Morris E., and Mackinnon S. Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Transfus Apher Sci. 32 (2005) 73-83
16. Peggs K.S., Thomson K., Hart D.P., et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 103 (2004) 1548-1556
17. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96 (2000) 2419-2425
18. Parker J.E., Shafi T., Pagliuca A., et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol. 119 (2002) 144-154
19. Cull G.M., Haynes A.P., Byrne J.L., et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol. 108 (2000) 754-760
20. Miflin G., Stainer C.J., Carter G.I., Byrne J.L., Haynes A.P., and Russell N.H. Comparative serial quantitative measurements of chimaerism following unmanipulated allogeneic transplantation of peripheral blood stem cells and bone marrow. Br J Haematol. 107 (1999) 429-440
21. Quantitative analysis of chimerism after allogeneic stem cell transplantation using multiplex PCR amplification of short tandem repeat markers and fluorescence detection. Leukemia 15 (2001) 303-306
22. Russell N.H., Byrne J.L., Faulkner R.D., Gilyead M., Das-Gupta E.P., and Haynes A.P. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 36 (2005) 437-441
23. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 53 (1958) 457-481
24. Bethge W.A., Hegenbart U., Stuart M.J., et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 103 (2004) 790-795
25. Bader P., Niethammer D., Willasch A., Kreyenberg H., and Klingebiel T. How and when should we monitor chimerism after allogeneic stem cell transplantation?. Bone Marrow Transplant 35 (2005) 107-119
26. Sykes M., Sheard M.A., and Sachs D.H. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med. 168 (1988) 2391-2396
27. Perez-Simon J.A., Caballero D., Diez-Campelo M., et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 16 (2002) 1423-1431
28. Keil F., Prinz E., Moser K., et al. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. Transplantation 76 (2003) 230-236
29. Sykes M., Szot G.L., Swenson K.A., and Pearson D.A. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med. 3 (1997) 783-787
30. Vriesendorp H.M. Aims of conditioning. Exp Hematol. 31 (2003) 844-854
31. Blazar B.R., Lees C.J., Martin P.J., et al. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J Immunol. 165 (2000) 4901-4909
32. Kolb H.J., Schmid C., Barrett A.J., and Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103 (2004) 767-776
33. Johnson B.D., Hanke C.A., and Truitt R.L. The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. Leuk Lymphoma 23 (1996) 1-9
34. Porter D.L., and Antin J.H. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med. 50 (1999) 369-386
35. Xia G., Truitt R.L., and Johnson B.D. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory t cells in early and long-term chimeras. Biol Blood Marrow Transplant 12 (2006) 397-407
36. Weiden P.L., Storb R., Tsoi M.S., Graham T.C., Lerner K.G., and Thomas E.D. Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance. J Immunol. 116 (1976) 1212-1219
37. Georges G.E., Storb R., Thompson J.D., et al. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood 95 (2000) 3262-3269
38. Tsoi M.S., Storb R., Dobbs S., and Thomas E.D. Specific suppressor cells in graft-host tolerance of HLA-identical marrow transplantation. Nature 292 (1981) 355-357
39. reg) cells block the breaking of tolerance in mixed chimeras. Biol Blood Marrow Transplant. 12 Suppl 1 (2006)
40. Mapara M.Y., and Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22 (2004) 1136-1151
41. Baron F., Sandmaier B.M., Zellmer E., Sorror M., Little M.T., and Storb R. Early donor lymphocyte infusion (DLI) does not consistently prevent graft rejection in dogs given DLA-identical marrows after 1 Gy total body irradiation (TBI). Biol Blood Marrow Transplant. 12 Suppl 1 (2006)